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Background: Hepcidin-25 is the master regulator of iron homeostasis. N-truncated isoforms of hepcidin-25 have been identified (hepcidin-20, -22, -24), although data on the concentrations of these isoforms is sparse.
Methodology: Serum was mixed with aqueous formic acid, and the supernatant loaded onto a 96-well-SPE-plate. Eluted analytes were analysed using LC-HR-MS. Forty-seven paired dipotassium-EDTA human plasma and serum samples were analysed.  
Results: The LLoQ was 1 µg/L (all analytes). Accuracy and precision was acceptable. There was a good correlation (R2 > 0.90, all analytes) between matrices. The median (range) serum hepcidin-20, -22, -24, and-25 concentrations measured were 4 (1–40), 8 (2–20), 8 (1–50), and 39 (1–334) µg/L, respectively.
Conclusion: LC-HR-MS is widely applicable to the measurement of hepcidin-25, and truncated isoforms. 





Hepcidin is a 25 amino acid polypeptide, primarily synthesised in the liver as preprohepcidin, an 84 amino acid polypeptide. Cleavage of preprohepcidin occurs to form a 60 amino acid (prohepcidin), which is then further cleaved to form the biologically active hepcidin-25. Hepcidin-25 is now regarded as the master regulator of iron homeostasis by binding to, and causing the internalisation and proteolysis of ferroportin-1 on the membranes of macrophages, enterocytes and hepatocytes [1]. This causes increased intracellular iron stores, decreased dietary iron absorption, and decreased circulating plasma iron concentrations [2]. Three N-terminal truncated isoforms of hepcidin-25 have been identified (hepcidin-20, hepcidin-22 and hepcidin-24) in plasma and urine [3–6], and are thought to be degradation products of hepcidin-25. Hepcidin-25 has been reported to be highly (89 %) protein bound, primarily to α-2 macroglobulin [7]. However, in contrast, another report suggests that less than 3 % of circulating hepcidin-25 is bound to plasma proteins [8]. Nothing is known regarding protein binding of other hepcidin isoforms. In-vitro studies have shown hepcidin-20, hepcidin-22 and hepcidin-24 to have little if any activity at the ferroportin receptor [3], although they may have some antimicrobial activity [9]., and Mmeasurement of hepcidin-20, rather than hepcidin-25 has been suggested to be helpful in the diagnosis of acute myocardial infarction [10]. However, few studies have measured reported the concentrations of hepcidin-20, or hepcidin-22 these N-truncated isoforms in either human serum or plasma, and to date, the concentrations of the recently identified hepcidin-24 isoform in human serum or plasma has not been reported.. 
There are a number of potential clinical applications for serum hepcidin-25 measurement, such as the differential diagnosis of iron deficient anaemia from anaemia of chronic disease, and to help predict response to oral iron. Furthermore, measurement of hepcidin-25, is anticipated to be useful in monitoring the effects of therapies when hepcidin agonists and antagonists are used [11]. With this in mind, a number of immunochemical and mass-spectrometric methods have been published for the measurement of plasma or serum hepcidin-25. However, significant variability between methods has been reported [12–14]. In part, this is likely due to N-truncated isoforms of hepcidin-25 cross-reacting with the antibodies used in hepcidin-25 immunochemical assays, therefore falsely elevating the measured ‘hepcidin-25’ concentration. The ability to separately identify and quantify each isoform of hepcidin-25 is a clear advantage of using mass spectrometry (MS), and a number of methods using liquid chromatography with tandem MS detection (LC-MS/MS) have been reported [15–21]. Although methods have been published for the measurement of hepcidin-25, a fully validated method for all commercially available isoforms of hepcidin (hepcidin-20, -22, -24, and -25) has not been published. Recently, the use of Orbitrap high resolution MS instruments (ThermoFisher Scientific) coupled with liquid chromatography have been reported for the measurement of hepcidin-25 [5,22]. These instruments have the advantage that data are acquired in full-scan mode, allowing retrospective interrogation for compounds not initially targeted. This approach recently enabled the identification of hepcidin-24 in human plasma [5].




Human hepcidin-20, -22, -24, -25, and isotopically labelled hepcidin-25 [(13C8,15N3)-hepcidin-25] for use as an internal standard (IS) were from Peptides International (Kentucky, USA). Amino acid sequences for hepcidin-20, -22, -24, and -25 were: ICIFCCGCCHRSKCGMCCKT, FPICIFCCGCCHRSKCGMCCKT, THFPICIFCCGCCHRSKCGMCCKT, and DTHFPICIFCCGCCHRSKCGMCCKT, respectively. Four disulphide bonds were present for all analytes at the following positions; Cys1–Cys8, Cys3–Cys6, Cys2–Cys4, and Cys5–Cys7. The purity of all compounds was greater than 95.9 %, however, the net peptide content ranged from 65.9–84.1 % [100 % for (13C8,15N3)-hepcidin-25]; all were supplied as trifluoroacetate salts. Quadruple charcoal-stripped human serum was from Sera Laboratories Ltd (West Sussex, UK). Formic acid (ACS reagent grade), trifluoroacetic acid (TFA), acetonitrile, water (all HPLC grade), phosphate buffered saline (PBS), and lyophilised human α‑2‑macroglobulin (> 98 % purity) were from Sigma Aldrich (Poole, UK). Protein LoBind tubes (0.5 and 1.5 mL) and protein LoBind 96 deep-well plates (0.5 mL volume) were from Eppendorf (Stevenage, UK). Oasis hydrophilic-lipophilic-balanced (HLB) µElution 96-well SPE plates (30 µm particle size, 2 mg packing per well) were obtained from Waters (Elstree, UK). 

Preparation of calibration, internal quality control, and internal standard solutions
Prior to use, charcoal-stripped human serum was analysed, and neither hepcidin-20, -22, -24, or -25 was detected. Stock solutions (100 mg/L, corrected for net peptide content) of each individual hepcidin, were prepared in 30 % (v/v) acetonitrile in deionised water containing 0.1 % (v/v) formic acid. Two calibration working solutions (1 mg/L and 4 mg/L, all analytes) were prepared by appropriate dilution of individual stock solutions with analyte-free charcoal-stripped human serum, into grade A volumetric glassware. A separate internal quality control (IQC) working solution was prepared (4 mg/L, all analytes) in analyte-free charcoal-stripped human serum. An IS stock solution (100 mg/L) was prepared in 30 % (v/v) acetonitrile in deionised water containing 0.1 % (v/v) formic acid.
To prepare calibration (hepcidin-20 to -24; 1, 2, 5, 10, 25, 50, and 100 µg/L, hepcidin-25; 1, 2, 5, 10, 50, 100, and 200 µg/L) and IQC (hepcidin-20 to -24; 4, 8, and 25 µg/L, hepcidin-25; 8, 75, and 150 µg/L) solutions, appropriate volumes of working stock solutions were pipetted into grade A volumetric glassware and made up to volume with analyte-free charcoal-stripped human serum. After standing overnight (2–8 ºC) and after thorough mixing, portions were transferred to 0.5 mL LoBind tubes and stored at -20 ºC until required. An IS stock solution (100 mg/L) was prepared in 30 % (v/v) acetonitrile in deionised water containing 0.1 % (v/v) formic acid and a Prior to use, charcoal-stripped human serum was analysed, and neither hepcidin-20, -22, -24, or -25 was detected. Wworking IS solution (1 mg/L) was prepared by dilution of the (13C8,15N3)-hepcidin-25 stock solution with 30 % (v/v) acetonitrile in deionised water containing 0.1 % (v/v) formic acid, and. Pportions were stored at -20 °C in 0.5 mL LoBind tubes until required.

Instrumentation and conditions
An Aria Transcend TLX-II system (ThermoFisher Scientific, San Jose, USA) consisting of four Accela 1200 high-pressure quaternary pumps, valve interface module, column oven and CTC PAL autosampler were used with a Q Exactive mass spectrometer (ThermoFisher Scientific, San Jose, USA). LC and MS instrument control was performed using Aria OS (version 2.0, ThermoFisher Scientific), and Xcalibur software (version 2.2, ThermoFisher Scientific), respectively. System eluents were: (A) 0.1% (v/v) aqueous formic acid, and (B) 0.1% (v/v) formic acid in acetonitrile. The eluent flow rate was delivered at 0.1 mL/min, using the following LC gradient; 5 % B for 1 min, ramped to 50 % B over 8 min, then stepped to 100 % for 1.5 min (flow-rate 0.4 mL/min) before returning to starting conditions for 1.5 min (flow-rate 0.4 mL/min). Prepared samples (100 µL) were injected onto an ACE C18 column (3 µm, 100 x 1.0 mm i.d., Hichrom Ltd, Theale, UK) maintained at 60 ºC. MS detection was carried out in positive-ion mode using heated electrospray ionization [spray voltage 4.0 kV; temperatures: vaporizer 150 ºC; capillary 350 ºC; auxiliary, sheath and sweep gases 10, 35 and 0 (arbitrary units), respectively;, S-lens voltage 90 V]. Full-scan MS data were acquired using a resolution setting of 70000, defined as full width at half maximum (FWHM) at m/z 200, with a scan range of 400–1000 m/z (Orbitrap settings: maximum injection time 200 ms, automatic gain control target 3 x 106 ions). External mass calibration was carried out on alternate days using a positive mass calibration solution. For all post-acquisition data processing using Xcalibur software, peak areas were generated by filtering full‑scan data using a mass extraction window of ± 5 ppm based on theoretical monoisotopic m/z values of the theoretical five most abundant isotopes of the [M+3]3+, [M+4]4+, and [M+5]5+ charge states. External mass calibration was carried out on alternate days using a positive mass calibration solution. Peak area ratios [hepcidin-20, -22, -24, and -25 all to (13C8,15N3)-hepcidin-25] were measured and used to construct individual calibration curves (1/x weighting, not forced through zero). Qualitative analyte identification criteria were: (i) LC retention time within ± 30 s (including co-elution with the internal standard for hepcidin-25), and (ii) m/z value of the protonated ions within ± 5 ppm. Samples where the concentration measured was above the calibration range were diluted appropriately with analyte‑free charcoal-stripped human serum prior to reanalysis.

Sample preparation
An Oasis HLB µElution, 96-well, SPE plate was conditioned by addition of methanol (200 µL) followed by deionised water (200 µL) while under vacuum. Sample (200 µL) was added to a 1.5 mL LoBind tube together with IS working solution (10 µL), and 0.1 % (v/v) aqueous formic acid (600 µL), followed by vortex mixing for 5 min, and centrifugation for 5 min (16060 x g). The entire supernatant was loaded onto the conditioned 96-well SPE plate, and allowed to flow freely under gravity for 5 min after which vacuum was applied until no supernatant remained. The plate was washed sequentially with 20 % (v/v) acetonitrile in deionised water (200 µL), and then deionised water (200 µL), both under vacuum. Analytes were eluted directly into 0.5 mL protein LoBind 96 deep-well plates with 70 % (v/v) acetonitrile in deionised water containing 1 % (v/v) TFA under vacuum (60 µL). After elution, 0.1 % (v/v) formic acid in deionised water (70 µL) was added to each extract. The 96-well plate was then transferred to the autosampler, and 100 µL injected onto the LC-HR-MS system. Samples where the concentration measured was above the calibration range were diluted appropriately with analyte‑free charcoal-stripped human serum prior to reanalysis.

Method validation
Intra- and inter-assay precision and accuracy were assessed by replicate analysis (N = 5) of IQC solutions on the same day and in duplicate on different days (N = 5), respectively. Lower limits of quantification (LLoQ) were assessed by dilution of calibration solution 3 with analyte-free charcoal-stripped human serum, and defined as the lowest concentration where accuracy was within 80–120 % of the nominal concentration, and imprecision was < 20 %. To ascertain extraction yield, matrix effect, and process efficiency (‘overall recovery’) all hepcidins [hepcidin-20 to -24; 8 µg/L, hepcidin-25, (13C8,15N3)-hepcidin-25 ; 75 µg/L] were added to analyte-free charcoal-stripped human serum either before extraction (A), or to analyte-free charcoal-stripped human serum post-extraction (B). All hepcidins were also added to 35 % (v/v) acetonitrile in deionised water containing 1 % (v/v) TFA (C). Peak area ratios (expressed as a percentage) of A to C, B to C, and B to A were calculated to ascertain process efficiency, matrix effects and extraction yield, respectively. Process efficiency was further ascertained by addition of all analytes (100 µg/L) to separate portions of serum from 5 patients with hereditary haemochromatosis [C282Y/C282Y homozygotewhere  (all analytes were below the LLoQ before fortification)], and comparison of the peak areas obtained to a directly injected solution containing all analytes in 35 % (v/v) acetonitrile in deionised water containing 1 % (v/v) TFA. 
Carry-over was assessed through consecutive analysis of prepared samples containing all analytes at low (L) and high (H) concentrations (5 and 500 µg/L, respectively) in the sequence; H, H, H, L, L, L. In order to ascertain the effect of increasing concentrations of α-2-macroglobulin on process efficiency, α-2-macroglobulin was added to separate portions of PBS containing all hepcidins (100 µg/L) at 1, 2, 3, and 4 g/L, which were allowed to equilibrate at room temperature for 2 hours before analysis. Prepared samples were then analysed in triplicate according to the protocol described herein.
To investigate analyte stability, all hepcidins were added to separate portions of analyte-free charcoal-stripped human serum (50 µg/L all analytes, except hepcidin-25 at 100 µg/L), and stored in the dark, in protein LoBind tubes (500 µL portions) at (i) at ambient room temperature, (ii) 2–8 ºC, and (iii) -20 ºC. Each solution was sampled at 0, 1, 2, 4, and 8 h, and after 1–5, 7, 14, 21, and 28 days. Samples were analysed in duplicate using freshly prepared calibration solutions. Freeze–thaw stability was assessed by freezing (-20 ºC for 23 h) and thawing (ambient room temperature, 1 h) a solution of analyte-free charcoal-stripped human serum containing individual hepcidins (each 50 µg/L). After thorough mixing, the solutions were analysed using freshly prepared calibration solutions that had not undergone freeze-thawing. Portions of solutions that remained were returned to the freezer until the following day (3 freeze–thaw cycles in total). Analyte stability on the autosampler tray (10 ºC) was investigated by preparing separate solutions of hepcidin-20, -22, -24, and -25 in 20 % (v/v) acetonitrile in deionised water containing 0.4 % TFA (v/v) at low (5 µg/L all analytes, except hepcidin-25 at 10 µg/L), and high (50 µg/L all analytes, except hepcidin-25 at 100 µg/L) concentrations. Portions of each solution were injected onto the LC-HR-MS system every hour for 24 hours.  Instability was defined as a deviation of ± 15 % from the concentration measured initially.
To ascertain whether there was degradation of any hepcidin isoform during the extraction process, each individual hepcidin was added to separate portions of analyte-free charcoal-stripped human serum (50 µg/L all analytes), and analysed in duplicate.

Patient samples
Whole blood from healthy volunteers (N = 46) was collected into BD Vacutainer SST II Advance tubes. Following centrifugation (12000 x g, 10 min), a portion of the serum was stored in 0.5 mL protein LoBind tubes at -20 ºC for one month until analysis. A further 47 Ppaired human serum (BD Vacutainer SST II Advance) and plasma (BD Vacutainer dipotassium EDTA) randomly selected samples from hospitalised patients (N = 47) that were submitted for routine biochemical and haematological analyses were collected, anonymised, and stored at 2–8 ºC for up to 4 h before centrifugation (12000 x g, 10 min).  Portions of plasma or serum Aliquots of excess sample following routine analysis were then anonymised and stored in 0.5 mL protein LoBind tubes at -20 ºC for up to one month until analysis. Samples were collected in accordance with protocols approved by the relevant institutional review board, and informed consent was obtained in accordance with the Declaration of Helsinki.  As excess sample was used and anonymised, ethical approval was not required. Statistical analysis was performed using Analyse-it (Analyse-it Software Ltd, Leeds, UK) for Microsoft Excel. To examine relationships, Spearman’s rank correlation coefficient simple linear regression analysis with calculation of bivariate correlation coefficients (r) using the Pearson’s product formula werewas performed, and. the difference between groups was evaluated using the Mann-Whitney U test. A p value < 0.05 was considered statistically significant.

Laboratory measurements




Extracted ion chromatograms together with analyte retention times, and a mass spectrum are shown in Figures 1 and 2, respectively. Calibration was linear (R2 > 0.90) for all analytes over the range studied. Intra- and inter-assay precision and accuracy are summarised in Table 1. The LLoQ was 1 µg/L for all analytes. No carryover was observed. Extraction yield, matrix effects, and process efficiency for all analytes in analyte-free stripped human serum are summarised in Table 2. Median (range) process efficiency for all analytes added to analyte-free human serum from 5 sources were; 36 (22–45), 25 (18–37), 23 (17–26), 24 (15–38), and 23 (15–32) % for hepcidin-20, -22, -24, -25, and (13C8,15N3)-hepcidin-25 respectively. Increasing the concentration of α-2-macroglobulin had no effect on process efficiency for any analyte. There was no identifiable degradation, or formation of any hepcidin isoform during the extraction process. No decrease in analyte concentration was observed over 24 h when stored on the autosampler, and all analytes were stable after 3 freeze–thaw cycles. 
At ambient room temperature, hepcidin-20 and -24 were stable for up to 5 days, hepcidin-22 for up to 1 week, and hepcidin-25 for up to 3 weeks. By week 4, concentrations of hepcidin-20 had declined to 15 % of those measured initially, whereas concentrations of hepcidin-22, -24, and -25 were some 38–44 % of those measured initially. 
When stored at 2–8 ºC, hepcidin-20 was stable for up to 1 week, and all other hepcidins for up to 3 weeks. After 1 month, concentrations of all analytes had declined to some 69–74 % of those measured initially. All analytes were stable when stored at -20 ºC for 1 month. 
The decline in concentrations of hepcidin-20, -24, and -25 when stored at ambient room temperature, and at 2–8 ºC, was not paralleled by the presence of other isoforms of hepcidin-25. However, the decline of hepcidin-22, was paralleled by increasing concentrations of hepcidin-20 when stored at ambient room temperature (Figure 3).

Volunteer and Ppatient samples
Forty-six samples were obtained from healthy volunteers; 20 samples were from male individuals [median, (range) age; 40 (24–68) yr], and 26 samples were from females [median, (range) age; 35, (24–61) yr]. Ferritin concentrations (median, range) were significantly lower (p = < 0.01) in females (55, 20–311 µg/L) as compared to males (89, 39–348 µg/L), as was transferrin saturation (males; 33, 16–63 %, females; 27, 12–54 %, p < 0.05). There was no significant difference between males and female for CRP (median 1, range < 1–10 mg/L, p = 0.56), iron (median 16.0, range 7.3–32.0 µmol/L, p = 0.12), and TIBC (median 57, range 46–70, p = 0.08). Hepcidin-25 (median, range) was 7 (1–31) µg/L, and although the median serum hepcidin-25 concentration was lower in females (6 µg/L) than males (11 µg/L), this was not statistically significant (p = 0.22). Hepcidin-25 was below the LLoQ (1 µg/L) in 5 samples (median, range ferritin; 39, 22–104 µg/L), and hepcidin-20, -22, and -24 were below the LLoQ (1 µg/L) in all samples. Hepcidin-25 was significantly correlated with ferritin (r = 0.48, p = < 0.05), and TIBC (r = -0.40, p = < 0.05), but it was not correlated with serum iron (r = 0.05, p = 0.76) or transferrin saturation (r = 0.16, p = 0.32),
Forty-seven paired plasma and serum samples were analysed, and t, 23 samples were from male patients [median, (range) age; 51 (21–88) yr], and 24 samples were from females [median, (range) age; 44, (21–84) yr]. Thhee results obtained on analysis of serum samples are summarised in Table 3. There was a strong and significant correlation (r = ≥ 0.95, p = < 0.05) between all analytes in plasma and serum (Figure 4). 
Hepcidin-25 was at measurable concentrations in 42 serum samples, however in only half or less of all samples were hepcidin-20, -22, -24 measureddetected, and the concentrations measured in serum were some 12–17 % of those of hepcidin-25. No samples contained detectable hepcidin-20, -22, or -24 in the absence of hepcidin-25. Correlations of serum hepcidin-25 to hepcidin-20, -22, and -24 are shown in Figure 5. Serum hepcidin-25 was strongly correlated to hepcidin-24 (N = 25, r = 0.88, p = < 0.05), but to a lesser extent with hepcidin-22 (N = 12, r = 0.57, p = 0.05), and hepcidin-20 (N = 35, r = 0.70, p = < 0.05). When samples with a serum hepcidin-25 > 100 µg/L were excluded, the correlation to hepcidin-22 was much improved (N = 6, r = 0.94, p = < 0.05). Hepcidin-24 was moderately correlated with hepcidin-22, and -20 (N = 12, r = 0.73, p = < 0.05, and N = 23, r = 0.72, p = < 0.05, respectively), and hepcidin-22 was again moderately correlated with hepcidin-20 (r = 0.62, p = < 0.05). In 12 (29 %) samples where hepcidin-25 was measured (median 98, range 15–133 µg/L), all other isoforms were also detected, median (range), hepcidin-20; 10 ([2–34]); hepcidin-22; 6 ([2–21]); and hepcidin-24; 16 ([3–26]) µg/L. 

Discussion
We present here an accurate, precise and sensitivea LC-HR-MS based method for the measurement of hepcidin-25 and N-truncated isoforms in human serum. Currently published LC-MS based methods for hepcidin-25 have used either protein precipitation [5, 15], ultrafiltration [17], magnetic nanoparticles [19] or solid phase extraction as sample preparation techniques [16, 18, 20–22]. However, we found protein precipitation using an organic solvent (e.g. acetonitrile) or aqueous trichloroacetic acid, gave unacceptable process efficiencies and matrix effects. Instead, we investigated the use of Waters Oasis µElution SPE plates since they are available in 96-well formats readily applicable to high-throughput analyses, come in a range of sorbent chemistries, and allow concentrations of the analyte through the use of small elution volumes. We found and found the HLB sorbent to provide optimum overall process efficiency with minimum minimal matrix effects, as compared to ion-exchange sorbents. This is in keeping with other investigators that have used the HLB sorbent [16, 18, 20–22] although a recently published method used OASIS µElution plates with a maximum-anion-exchange sorbent chemistry [21].
A number of LC-MS/MS methods have been published for the measurement of hepcidin-25. However, hepcidin-25 is able to absorb substantial fragmentation energies before fragmentation occurs, and when hepcidin-25 does fragment, there are many product ions of low or variable intensities [19]. Those methods that have used this approach, monitor product ions which are either of low abundance [16], or of a low m/z [15], which lack specificity. Furthermore, these methods monitor only a single charge state, and a single isotope of that charge state. However, there is the possibility that charge state distribution may differ between samples thereby compromising accurate quantitation. By using an Orbitrap mass-analyser, and acquiring data in full-scan mode, the method reported here uses the top 5 most abundant isotopes (88 % of the theoretical charge) of the top 3 most predominant charge states for quantitation in post-acquisition data processing. A disadvantage to this approach however, is that monitoring a number of isotopes and charge states can reduce the signal to noise ratio, thereby reducing sensitivity. Be this as it may, a LLoQ of 1.0 µg/L was still achieved for all analytes which is comparable to reported LC-MS/MS methods for hepcidin-25 [16, 17, 20]. Recently, two LC-HR-MS based methods using Orbitrap technology have been reported for the measurement of hepcidin-25 [5, 22]. The first acquires full-scan data, yet only uses the top 3 isotopes of a single charge state in post-acquisition data processing, and has concentration-dependent process efficiency likely due to saturation of the C-trap [5]. The second method undertakes parallel reaction monitoring when using a Q Exactive [22], yet only monitors a single charge state. 
With regard to stability, we found all hepcidins to be stable at ambient room temperature for at least 5–7 days (hepcidin-25; 3 weeks). Others have reported serum hepcidin-25 to be relatively stable for 16 h [18] in fortified samples, when stored at room temperature. In patient samples stored at room temperature, investigators have reported hepcidin-25 to be stable for one day, and after day 7 it had declined by 45 % [3]. It is not clear why we found hepcidin-25 to be stable at ambient room temperature for a period longer than those reported by other investigators. But,; iIt is possible that the use of protein LoBind tubes, that are specifically designed to reduce protein adsorption aided stability, but we did not specifically investigate this.however, it is likely that stability is dependent on the matrix, and may be different between those samples fortified with hepcidin-25 and those with native hepcidin-25. Despite our finding that hepcidin isoforms are stable at ambient room temperature for at least 5–7 days, the time samples/calibrators/IQCs are spent at room temperature should be kept to a minimum, and stored at 2–8 ºC for no longer than 1 week. Furthermore, the time between sample collection and storage at -20 ºC should also be kept to a minimum.   It is also possible that the use of protein LoBind tubes, that are specifically designed to reduce protein adsorption aided stability, but we did not specifically investigate this. It is interesting to note that the decline in hepcidin-24, and -25 concentrations was not paralleled by measurable concentrations of the smaller N-truncated isoforms of these analytes, as would be expected if they were degradation products. In contrast, however, the decline in hepcidin-22 was paralleled by an increase in hepcidin-20 when stored at ambient room temperature. This would suggest that during storage, the decline of hepcidin-20, -24, and -25 is due to adsorption onto the container wall, endogenous compounds or through aggregation,. Aalthough  degradation to other potential hepcidin isoforms (i.e. hepcidin-19, -21, and -23) other than those not investigated here cannot be ruled out. 
Traditionally, triple quadrupole mass–analysers have been used for the quantitation of small molecules, including peptides and proteins. This is in part due to the selectivity and sensitivity that can be obtained with these instruments. With this in mind, a number of LC-MS/MS methods have been published for the measurement of hepcidin-25. However, hepcidin-25 is able to absorb substantial fragmentation energies before fragmentation occurs, and when hepcidin-25 does fragment, there are many product ions of low or variable intensities [19]. Those methods that have used this approach, monitor product ions which are either of low abundance [16], or of a low m/z [15], which lack specificity. Furthermore, these methods monitor only a single charge state, and a single isotope of that charge state; however, there is the possibility that charge state distribution may differ from sample to sample. The method reported here has the advantage that the top 5 most abundant isotopes (88 % of the theoretical charge) of the top 3 most predominant charge states are monitored and used for the construction of calibration curves and for quantitation in post-acquisition data processing, and that acquisition of the data in full-scan mode allows retrospective data interrogation. A disadvantage to this approach is that monitoring a number of isotopes and charge states can reduce the signal to noise ratio, and therefore reduce sensitivity; however, a LLoQ of 1.0 µg/L was still achieved for all analytes which is comparable to reported LC-MS/MS methods for hepcidin-25 [16, 17, 20]. Recently, two LC-HR-MS based methods using Orbitrap technology have been reported for the measurement of hepcidin-25 [5, 22]. The first acquires full-scan data, yet only monitors the top 3 isotopes of a single charge state in post-acquisition data processing, and has concentration-dependent process efficiency likely due to saturation of the C-trap [5]. The second method undertakes parallel reaction monitoring when using a Q Exactive [22], yet only monitors a single charge state. 
	 With regard to patient samples, wWe found an excellenta strong correlation between EDTA plasma and serum for hepcidin-25, which is in keeping with other reports [17, 23]. There was also a strong correlation To date the correlation between human plasma and serum for hepcidin-20, -22, and-24.  has not been reported, however we found an excellent correlation between these two matrices for these analytes. Some investigators have reported aA bias of some 24 % for hepcidin-25 between human EDTA plasma and serum has been reported [21], . While whereas others investigators have reported negligible differences between lithium-heparin plasma and serum [24–25], and heparinised and citrated plasma [3] for hepcidin-25negligible.  Since routine biochemical tests for assessing iron status (e.g. ferritin, transferrin saturation) are performed using serum, this may be the most suitable sample type for hepcidin measurement as it would potentially allow analysis of all biomarkers on the same sample. differences in hepcidin-25 concentrations between lithium-heparin plasma and serum [24–25], and heparinised and citrated plasma [3], while marginally higher concentrations (8 %) of hepcidin-25 in EDTA plasma as compared to heparinised plasma have been observed [3]. It is not clear why there are differences in hepcidin-25 between serum and plasma when collected using different anti-coagulants, but wWhere possible, the matrix used to prepare calibration and internal quality control solutions should match as closely as possible, that of the patient samples analysed.  Furthermore, since routine biochemical tests for assessing iron status (e.g. ferritin, transferrin saturation) are performed using serum, this may be the most suitable sample type for hepcidin measurement as it would potentially allow analysis of all biomarkers on the same sample. In the method described here, calibration and IQC solutions were prepared in charcoal-stripped human serum. Although this matrix is not directly comparable to the patient serum samples analysed, as hepcidin-25 is endogenous, obtaining analyte-free human serum is difficult. The use of stripped-human serum for preparation of calibration and IQCs is common practice when an endogenous analyte is to be measured, and this matrix has been used by other investigators for hepcidin-25 measurement with success [19, 20]. Analyte-free serum from a patient with juvenile haemochromatosis has been used in a published report [3] for preparation of calibration and IQC solutions, and although would be suitable to use for matrix matching, it was not readily available for the method developed here.


In samples from healthy volunteers, concentrations of hepcidin-25 were comparable to published reports [20, 25], and enabled a method-specific reference range for hepcidin-25 to be ascertained, which is essential given the considerable variability between methods that has been reported [12, 13, 14]. However, only a relatively small number of samples were analysed, and further work should be undertaken to establish sex-specific, and age-related reference ranges. Neither hepcidin-20, -22, or -24 were detected in any sample from healthy volunteers. By comparison, mean serum hepcidin-20, -22, and -25 concentrations of 2.6, 0.97, and 12.4 µg/L respectively in healthy volunteers [6], and mean hepcidin-20, and -25 concentrations of 7.3 µg/L, and 17.2 µg/L, respectively in samples from a general population have been reported, although hepcidin-20 was only detected in 54 % (N = 854) of these samples [27]. In paired plasma/serum samples, the concentrations of hepcidin-25 measured were broadly comparable to those reported by other investigators in both healthy individuals and those with various disease states when measured using LC-MS/MS [19, 25–26], as are those of hepcidin-20, and -22 [6, 27]. A significant limitation of this report is that the patient samples analysed were from hospitalised patients where the reason for admission to the hospital was not available, but who are likely to have conditions associated with inappropriate hepcidin-25 concentrations (e.g. inflammation, chronic kidney disease). Yet, our data provide an indication of the concentrations of hepcidin-25, and N-truncated isoforms to be encountered in clinical practice. The concentrations of serum and plasma hepcidin-25 measured here are broadly comparable to those reported by other investigators in healthy individuals and various disease states when measured using LC-MS/MS [19, 25–26]. There are limited data regarding the concentrations of the smaller N-truncated forms of hepcidin-25 present in human plasma or serum; however, the concentrations of hepcidin-20, and hepcidin-22 measured here are broadly comparable to those measured by other investigators [6, 27]. There are currently no data regarding theon serum hepcidin-24 concentrations of hepcidin-24 in patients, and we have ascertained the concentrations of this isoform to be comparable to those of hepcidin-20, and -22; approximatelysome 10–20 % of hepcidin-25. It should be remembered though, that a significant limitation of this report is that samples were from hospitalised patients where clinical details were not available, but who are likely to have conditions associated with inappropriate hepcidin-25 concentrations (e.g. inflammation, chronic kidney disease). The developed method is therefore suitable for measuring hepcidin isoform concentrations in a clinical setting. However, only a relatively small number of samples from healthy volunteers were analysed, and further work should be undertaken to establish sex-specific, and age-related reference ranges, and further studies are required to ascertain whether the concentrations of each isoform vary depending on the disease state.
	These N-truncated isoforms of hepcidin-25 are generally considered to be degradation products of hepcidin-25 that may occur in-vivo or in-vitro. There is also the possibility that hepcidin-20, -22, and -24 are formed directly from hepcidin-25 during sample preparation. Certainly, they have been shown to appear when hepcidin-25 containing EDTA, heparin, and citrated human plasma is incubated at 37 °C [5]. However, in this study, when hepcidin-25 was added to stripped human serum, no hepcidin-25 isoform was found to be formed during the extraction process.
We identified a strong correlation between hepcidin-25 and hepcidin-24, and between hepcidin-25 and hepcidin-22 when serum hepcidin-25 concentrations were < 100 µg/L. This suggests that hepcidin-24 and hepcidin-22 may be direct degradation products of hepcidin-25, although they may still be directly generated from pro-hepcidin. Other investigators have found a strong and significant correlation between hepcidin-25, and hepcidin-20, and hepcidin-22 [6, 27], which is in part reflective of our data. However, these studies report concentrations from healthy volunteers, whereas the samples analysed in this study are frominclude patients with various disease states, and it is possible that the ratio of hepcidin-25 to the other isoforms of hepcidin-25 may differ depending on the disease state.  
N-truncated isoforms of hepcidin-25 are generally considered to be degradation products of hepcidin-25 that may be formed in-vivo or in-vitro. Certainly, they have been shown to appear when hepcidin-25 containing EDTA, heparin, and citrated human plasma is incubated at 37 °C [5]. There is also the possibility that hepcidin-20, -22, and -24 are formed directly from hepcidin-25 during sample preparation. However, in this study, when hepcidin-25 was added to stripped human serum, neither hepcidin-20, -22, or -24 were detected following the extraction procedure. 

Conclusion
Presented here is a fully validated LC-HR-MS assay for the measurement of not only hepcidin-20, -22, and -25, but also includes the recently identified hepcidin-24 isoform. We report here for the first time, serum concentrations of hepcidin-24, which were found to be comparable to those of hepcidin-20, and -22. We also identified a strong correlation between dipotassium EDTA plasma and serum for all analytes (R2 ≥ 0.90), and a good correlation between serum hepcidin-24 and hepcidin-25 (R2 = 0.89).

Future Perspectives




	Hepcidin-25 regulates the iron homeostasis by binding to, and causing the internalisation and proteolysis of ferroportin-1.
	Hepcidin-20, -22, and recently hepcidin-24 have been identified. However, published concentrations of hepcidin-20, and -22 are scant, and concentrations of hepcidin-24 have not been reported to date. 
	A fully validated method for serum hepcidin-20, -22, -24, and -25 by LC-HR-MS was developed, and applied to 47 paired human plasma and serum samples, and 46 samples from healthy volunteers
Methods
	Sample (200 µL) was mixed with internal standard [(13C8,15N3)-hepcidin-25, 10 µL], and 0.1 % (v/v) aqueous formic acid (600 µL). Supernatant was loaded onto a Waters Oasis µElution 96-well SPE plate, and analytes eluted under vacuum with 70 % (v/v) acetonitrile in deionised water containing 1 % (v/v) TFA (60 µL). A portion (100 µL) analysed by LC-HR-MS.
	Data was acquired in full-scan mode (m/z 400–1000), using high resolution mass-spectrometry and the sum of the [M+3H]3+, [M+4H]4+, and [M+5H]5+ of each analyte used for quantitation 
Results and discussion
	Calibration was linear (R2 > 0.90) for all analytes over the ranges studied.
	LLoQ was 1 µg/L (all analytes)
	Intra-, and inter-assay accuracy and precision were acceptable.
	There was a good correlation between human plasma and serum for all analytes
	In healthy volunteers the median (range) hepcidin-25 concentration measured was 7 (1–31) µg/L. Hepcidin-20, -22, and -24 were not detected in any volunteer sample
	In paired plasma/serum samples, Concentrations of hepcidin-20, -22, and -24 concentrations were some 10–20 % of those of hepcidin-25 (range 1–334 µ/L)
	There was a strong correlation between hepcidin-25 and hepcidin-24 in human serum (r = 0.88), but a weaker correlation between hepcidin-25 and hepcidin -22 (r = 0.57), and hepcidin-20 (r = 0.70). 
	LC-HR-MS has been shown to be suitable for the measurement of hepcidin isoforms in human serum, and further studies are required to ascertain their clinical role. 



















Figure 5. Correlation of hepcidin-25 to other hepcidin isoforms in human serum. Scatterplots between hepcidin-25, and (A) hepcidin-20, (B) hepcidin-22, and (C) hepcidin-24 concentrations. Solid line: simple linear regression, dashed lines: 95% confidence intervals.

Table 1. Summary accuracy and precision data. 
	Analyte
	Hepcidin-20	Hepcidin-22	Hepcidin-24	Hepcidin-25
Intra-assay (N = 5)												
Nominal concentration (µg/L)	4	8	25	4	8	25	4	8	25	8	75	150
Mean measured concentration (µg/L)	4	9	26	4	8	24	4	9	30	9	80	164
RSD (%)	11	14	6	< 1	6	7	11	10	9	9	2	6
Accuracy (% nominal)	100	113	104	100	100	96	100	113	120	113	107	109
Inter-assay  (N = 5)												
Nominal concentration (µg/L)	4	8	25	4	8	25	4	8	25	8	75	150






Table 2. Extraction yield, matrix effect, and process efficiency for all analytes (hepcidin-20 to -24; 8 µg/L, hepcidin-25, (13C8,15N3)-hepcidin-25; 75 µg/L) in analyte-free stripped human serum. 
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